Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 9 | Vintage Vibes

Find Out All About Mizuho's Top China Internet Sector Pick

Mizuho analyst James Lee recently hosted an investor call with Baidu, Inc (NASDAQ: BIDU) management. Firstly, Lee noted that the reopening has been orderly, and advertising is recovering faster than Cloud.

Benzinga

Thinking About Buying Stock Or Options In Robinhood Markets, Nio, Tesla Or Etsy?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Robinhood Markets, Nio, Tesla and Etsy:

Benzinga

Tesla, Rivian and NIO See Estimates and Price Targets Slash By Mizuho Post Battery Industry Call

Mizuho hosted a battery industry call looking at critical challenges, ramps, new technologies, and the longer-term outlook. It listed the key takeaways in a note titled "Battery Takeaways: Tesla the Leader, LFP Cost-Effective, Solid State Too Far Away."

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Mizuho Maintains Buy Rating for Equity Residential: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Equity Residential (NYSE:EQR) and lower its price target from $84.00 to $79.00. Shares of Equity Residential are trading up 2.32% over the last 24 hours, at $73.48 per share. A move to $79.00 would account for a 7.5% increase from the…

Benzinga

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease. Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

Benzinga

Mizuho Maintains Buy Rating for Alexandria Real Estate: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Alexandria Real Estate (NYSE:ARE) and lower its price target from $219.00 to $172.00. Shares of Alexandria Real Estate are trading up 1.78% over the last 24 hours, at $135.77 per share.

Benzinga

Mizuho Remains Bullish On Affirm - Read Why

Mizuho analyst Dan Dolev revisited its Affirm Holdings, Inc (NASDAQ: AFRM) securitization trust and delinquency tracker. With the updated data points for Calendar 2Q, trends look slightly less optimistic versus April, noted Dolev.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Benzinga

This Analyst Believes Negative Sentiment, Macro Headwinds As An Opportunity To Step In For Micron Technology and Western Digital

Mizuho analyst Vijay Rakesh slashed price targets on Micron Technology, Inc (NASDAQ: MU) to $95, from $113 (66% upside), and Western Digital Corp (NASDAQ: WDC) to $68, from $72 (44

Benzinga

Mizuho Sees Qualcomm, Qorvo, Skyworks Well Positioned For Global 5G Ramps Amid Odds - Read Full Take

Mizuho analyst Vijay Rakesh reiterated Buy on Qualcomm Inc (NASDAQ:QCOM), Qorvo, Inc (NASDAQ:QRVO), and Skyworks Solutions, Inc (NASDAQ:SWKS). However, he slashed the price targets of Qualcomm from $185 to $168 (34% upside), Qorvo from $128 to $110 (12% upside), and Skyworks from $170 to $150 (62% upside). His checks into the handset supply chain indicated downside risk…

Benzinga

6 Adobe Analysts React To Q2 Earnings Beat, Guidance Cut, Heightened Execution Risks

Adobe Inc (NASDAQ: ADBE) shares traded slightly higher on Friday after the company's full-year guidance disappointed Wall Street.

Benzinga

Mizuho Cuts WEC Energy's Price Target By 13%

Mizuho Securities analyst Anthony Crowdell lowered the price target on WEC Energy Group Inc (NYSE:WEC) to $93 (an upside of 3%) from $107 while maintaining the Neutral rating on the shares. Mizuho hosted investor meetings with WEC’s Executive Chairman Gale Klappa and CFO Xia Liu. Crowdell says that the management highlighted the strong 6-7% EPS…

Benzinga

Mizuho Expects EV Stocks Like Nio, Tesla, Rivian Set To Gain - Here's How

Mizuho analyst Vijay Rakesh sees BEV (Battery electric vehicle) as a bright spot amid macro headwinds led by China rebounding.

Benzinga

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Mizuho Views AMD, Nvidia, Qualcomm

Mizuho analyst Vijay Rakesh included Gigabyte, a distributor of GPUs and a motherboard OEM, and Zhen Ding, a leading PCB supplier in coverage post-Asia tech series checks.

Benzinga

Read Why Mizuho Re-rated Adobe Ahead Of Its 2Q Earnings

Adobe Inc (NASDAQ: ADBE) will report its 2Q results on June 16, Mizuho analyst Gregg Moskowitz noted.

Benzinga

10 Biggest Price Target Changes For Friday

Mizuho cut Adobe Inc. (NASDAQ: ADBE) price target from $600 to $530. Adobe shares fell 1.1% to $421.77 in pre-market trading.

Benzinga

Mizuho's Bullish Re-Rating On PayPal Had An Apple Connection - Read To Know

Mizuho analyst Dan Dolev's proprietary survey of PayPal Holdings, Inc's (NASDAQ:PYPL) Venmo and Apple Inc (NASDAQ:AAPL) Apple Pay exhibited a "strong appetite" to tap to pay with Venmo if Apple opened up its near field communication to Venmo. Dolev estimates that tap-to-pay with Venmo could present a 10% total payment volume and 15%-20% sales upside given Venmo's…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Analysts Reacted To Microsoft's Outlook Revision

Microsoft Corp (NASDAQ:MSFT) updated its Q4 and FY23 guidance due to recent unfavorable currency headwinds. Microsoft cited an incremental $460 million headwind from FX to its total revenue guidance issued in late April, representing slightly less than a 100bps delta on total revenue. Microsoft now expects revenue of $51.94 billion - $52.74 billion…

Benzinga

5 CrowdStrike Analysts React To Q1 Earnings Beat, Guidance Hike, Potential Hiring Ramp

CrowdStrike Holdings Inc (NASDAQ: CRWD) shares traded down by 6.2% on Friday after the company reported a first-quarter earnings beat and raised its full-year guidance.

Benzinga

Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness

Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for psychosis in Alzheimer's disease.

Benzinga

Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock

Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for ARQT.

Benzinga

Why Did Mizuho Cut Price Target On This CAR-T Stock, But Remain Bullish

Mizuho met Cabaletta Bio Inc (NASDAQ: CABA) management team after last week's data release at ASGCT.

Benzinga

Here's Why Mizuho Remains Incrementally Positive On Uber, Meta, Baidu, JD

Mizuho analyst James Lee recently met with investors and discussed U.S. and China internet coverage. With concerns about U.S. consumer demand and economic outlook, Lee senses that sentiment on China's Internet is improving.

Benzinga

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.